Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis

PHASE2CompletedINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

November 28, 2016

Primary Completion Date

April 17, 2019

Study Completion Date

August 16, 2019

Conditions
Moderate Active Ulcerative Colitis
Interventions
DRUG

E6007

once daily administration

DRUG

Placebo

once daily administration

Trial Locations (64)

Unknown

EA Pharma Trial Site #1, Nagakute

EA Pharma Trial Site #1, Nagoya

EA Pharma Trial Site #2, Nagoya

EA Pharma Trial Site #3, Nagoya

EA Pharma Trial Site #1, Toyoake

EA Pharma Trial Site #1, Toyota

EA Pharma Trial Site #1, Hirosaki

EA Pharma Trial Site #2, Hirosaki

EA Pharma Trial Site #1, Sakura

EA Pharma Trial Site #1, Urayasu

EA Pharma Trial Site #1, Matsuyama

EA Pharma Trial Site #1, Ōgaki

EA Pharma Trial Site #1, Takasaki

EA Pharma Trial Site #1, Fukuyama

EA Pharma Trial Site #1, Obihiro

EA Pharma Trial Site #1, Sapporo

EA Pharma Trial Site #2, Sapporo

EA Pharma Trial Site #1, Nishinomiya

EA Pharma Trial Site #1, Kanazawa

EA Pharma Trial Site #2, Kanazawa

EA Pharma Trial Site #1, Morioka

EA Pharma Trial Site #1, Takamatsu

EA Pharma Trial Site #2, Takamatsu

EA Pharma Trial Site #1, Kamakura

EA Pharma Trial Site #1, Kawasaki

EA Pharma Trial Site #1, Sagamihara

EA Pharma Trial Site #1, Yokohama

EA Pharma Trial Site #1, Tsu

EA Pharma Trial Site #1, Sendai

EA Pharma Trial Site #2, Sendai

EA Pharma Trial Site #1, Nagaoka

EA Pharma Trial Site #1, Kurashiki

EA Pharma Trial Site #1, Sayama

EA Pharma Trial Site #1, Suita

EA Pharma Trial Site #1, Kawagoe

EA Pharma Trial Site #1, Izumo

EA Pharma Trial Site #1, Shimotsuga

EA Pharma Trial Site #1, Bunkyo

EA Pharma Trial Site #1, Chūō

EA Pharma Trial Site #1, Hachiōji

EA Pharma Trial Site #1, Minato

EA Pharma Trial Site #2, Minato

EA Pharma Trial Site #1, Mitaka

EA Pharma Trial Site #1, Shinagawa

EA Pharma Trial Site #1, Shinjuku

EA Pharma Trial Site #1, Ube

EA Pharma Trial Site #1, Kofu

EA Pharma Trial Site #1, Chiba

EA Pharma Trial Site #1, Fukuoka

EA Pharma Trial Site #2, Fukuoka

EA Pharma Trial Site #1, Hiroshima

EA Pharma Trial Site #2, Hiroshima

EA Pharma Trial Site #1, Kagoshima

EA Pharma Trial Site #1, Kumamoto

EA Pharma Trial Site #1, Kyoto

EA Pharma Trial Site #2, Kyoto

EA Pharma Trial Site #1, Nagasaki

EA Pharma Trial Site #1, Niigata

EA Pharma Trial Site #1, Okayama

EA Pharma Trial Site #1, Osaka

EA Pharma Trial Site #2, Osaka

EA Pharma Trial Site #1, Saga

EA Pharma Trial Site #2, Saga

EA Pharma Trial Site #1, Toyama

All Listed Sponsors
lead

EA Pharma Co., Ltd.

INDUSTRY

NCT03018054 - Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis | Biotech Hunter | Biotech Hunter